Home Cart Sign in  
Chemical Structure| 886766-28-5 Chemical Structure| 886766-28-5

Structure of 886766-28-5

Chemical Structure| 886766-28-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 886766-28-5 ]

CAS No. :886766-28-5
Formula : C11H20N2O2
M.W : 212.29
SMILES Code : C(C)(C)(C)OC(=O)N1CC2(NCC1)CC2
MDL No. :MFCD08685931
InChI Key :XXKCYKIJWLFVDG-UHFFFAOYSA-N
Pubchem ID :46942212

Safety of [ 886766-28-5 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 886766-28-5 ] Show Less

Physicochemical Properties

Num. heavy atoms 15
Num. arom. heavy atoms 0
Fraction Csp3 0.91
Num. rotatable bonds 3
Num. H-bond acceptors 3.0
Num. H-bond donors 1.0
Molar Refractivity 66.04
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

41.57 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.79
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.83
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.53
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.15
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.05
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.27

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.48
Solubility 7.01 mg/ml ; 0.033 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.29
Solubility 11.0 mg/ml ; 0.0518 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.82
Solubility 3.19 mg/ml ; 0.015 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.01 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.74

Application In Synthesis of [ 886766-28-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 886766-28-5 ]

[ 886766-28-5 ] Synthesis Path-Downstream   1~11

  • 1
  • [ 591-50-4 ]
  • [ 886766-28-5 ]
  • [ 1254981-66-2 ]
YieldReaction ConditionsOperation in experiment
31% With cesium hydroxide; In dimethyl sulfoxide; at 120℃; for 0.666667h;Sealed tube; A stirred solution of <strong>[886766-28-5]4,7-diaza-spiro[2.5]octane-7-carboxylic acid tert-butyl ester</strong> (0.1 g, 0.471 mmol) [C.A.S. 886766-28-5] , iodobenzene (0.026 ml, 0.236) and CsOH (0.079 g, 0.471 mmol) in DMSO (1 ml) was heated in a sealed tube at 1200C for 20 min. After cooling, additional <strong>[886766-28-5]4,7-diaza-spiro[2.5]octane-7-carboxylic acid tert-butyl ester</strong> (2 eq.) was added, and the mixture was then heated at 1200C for 20 min. The mixture was cooled.The mixture was washed with NH4Cl (aqueous sat. solution) was added and extracted with Et2O. The organic phase was separated, washed with water, dried (Na2SO4) and concentrated in vacuo. The crude product was purified by manifold (Sep-Pak.(R). silica cartridge; DCM as eluent). The desired fractions were collected and concentrated in vacuo to yield intermediate D61 (0.021 g, 31percent) as a white solid.
  • 3
  • [ 886766-28-5 ]
  • [ 1200114-08-4 ]
YieldReaction ConditionsOperation in experiment
Step 2:4-(trifluoroacetyl)-4,7-diazaspiro[2.5]octane hydrochloridePyridine (500 mul) and trifluoroacetic anhydride (786 mul, 5.64 mmol) were added to a dichloromethane (10 ml) solution of the compound (1.0 g, 4.70 mmol) obtained in Step 1 above under ice cooling and the resulting mixture was stirred for 15 minutes.After completion of the reaction, trifluoroacetic acid (6 ml) was added and the resulting mixture was stirred at room temperature for 1 hour.The reaction solvent was evaporated under reduced pressure and then the residue was subjected to azeotropic distillation with toluene.The residue was diluted with chloroform and the organic layer was washed with saturated aqueous sodium bicarbonate solution and brine and dried over anhydrous sodium sulfate.The solvent was evaporated under reduced pressure and the residue obtained was purified by silica gel column chromatography [chloroform:methanol = 40:1 (v/v)].The residue obtained was subjected to azeotropic distillation with 4 N hydrochloric acid/dioxane and then dried under reduced pressure to give the title compound (751 mg, 65percent) as a colorless solid.1H-NMR (400 MHz, DMSO-d6) delta: 1.15-1.21 (4H, m), 3.14-3.19 (2H, m), 3.24 (2H, t, J=5.4 Hz), 3.84-3.91 (2H, m).MS (ESI) m/z: 209 [(M+H)+].
  • 4
  • [ 886766-28-5 ]
  • [ 1403676-74-3 ]
  • tert-butyl 4-((1s,4s)-4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)cyclohexyl)-4,7-diazaspiro[2.5]octane-7-carboxylate [ No CAS ]
  • tert-butyl 4-((1r,4r)-4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)cyclohexyl)-4,7-diazaspiro[2.5]octane-7-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
0.4%; 2.3% To a solution of tert-b tyl 4,7-diazaspiro[2.5]octane-7-carboxylate (0.16 g, 0.73 mmol) and 4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)cyclohexanone (0.20 g, 0.67 mmol) in DCE (5 mL) at room temperature under nitrogen was added acetic acid (76.0 mu, 1.30 mmol) and sodium triacetoxyborohydride (0.35 g, 1.7 mmol). The mixture was heated at 45 °C for 3 days. The reaction formed a major side product (alcohol) from ketone starting material. The mixture was quenched with saturated NaHC03 (aq.). The organic layer was separated and the aqueous layer was extracted once with DCM. The combined organic phases were concentrated under reduced pressure and purified by preparative HPLC. The pure fractions were combined, neutralized with saturated NaHC03 (aq.), and concentrated under reduced pressure. The aqueous residue was extracted twice with DCM and the combined organic layers were dried over anhydrous Na2S04, filtered and concentrated under reduced pressure to afford the more polar title compound as an off-white gum (7.7 mg, 2.3percent). The less polar cis analog was also obtained as an off-white gum (1.2 mg, 0.4percent). Exact mass calculated for C25H37FN2O5S: 496.2, found: LCMS m/z = 497.4 [M+H]+; lU NMR (400 MHz, CDC13) delta ppm 0.55-0.64 (m, 2H), 0.66-0.72 (m, 2H), 1.08-1.36 (m, 4H), 1.45 (s, 9H), 1.75-1.89 (m, 1H), 1.93-2.02 (m, 2H), 2.09-2.18 (m, 2H), 2.87-2.97 (m, 1H), 3.03 (s, 3H), 3.08-3.13 (m, 2H), 3.17 (s, 2H), 3.40 (bs, 2H), 3.90 (d, J = 6.32 Hz, 2H), 7.06 (t, J = 8.21 Hz, 1H), 7.62-7.66 (m, 1H), 7.66-7.70 (m, 1H).
  • 5
  • [ 886766-28-5 ]
  • 3-methyl-1-(tetrahydropyran-2-yl)-6-[4-(tetrahydropyran-2-yloxy)phenyl]-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid sodium salt [ No CAS ]
  • 4-{3-methyl-1-(tetrahydropyran-2-yl)-6-[4-(tetrahydropyran-2-yloxy)phenyl]-1H-pyrazolo[3,4-b]pyridine-4-carbonyl}-4,7-diazaspiro[2.5]octane-7-carboxylic acid tert-butyl ester [ No CAS ]
YieldReaction ConditionsOperation in experiment
66% With 2-bromo-1-ethylpyridin-1-ium tetrafluoroborate; N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃; To a suspension of 300 mg of 3-methyl-1 -(tetrahydro-pyran-2-yl)-6-[4-(tetrahydro- pyran-2-yloxy)-phenyl]-1 H-pyrazolo[3,4-b]pyridine-4-carboxylic acid sodium salt in 7.5 ml of DCM were added 0.12 ml of Hunig's base, 376 mg of BEP and 146 mg of<strong>[886766-28-5]4,7-diaza-spiro[2.5]octane-7-carboxylic acid tert-butyl ester</strong>. The reaction was stirred overnight at r.t.. For workup it was diluted with water and DCM and the layers were separated. The organic layer was washed with water twice, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica, heptane/EtOAc gradient) to obtain 280 mg (66%) of the title compound. LC/MS (Method LC4): Rt = 1 .24 min; m/z = 632.20 [M+H]+.
  • 6
  • [ 886766-28-5 ]
  • [ 823-62-1 ]
  • tert-butyl 4-(5-amino-6-chloro-1,2,4-triazin-3-yl)-4,7-diazaspiro[2.5]octane-7-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
53% With N-ethyl-N,N-diisopropylamine; In 1,4-dioxane; at 155℃; for 9.5h;Microwave irradiation; A vial was charged with 5-amino-3,6-dichloro-l,2,4-triazine (108.5 mg, 0.658 mmol), diisopropylethylamine (0.5 mL, 2.87 mmol), tert-butyl 2-(4,7-diazaspiro[2.5]octan-7- yl)acetate (154.8 mg, 0.650 mmol) in dioxane (2.5 mL). The mixture was heated at 155 C for 9.5 h using microwave. The mixture was concentrated to remove all of solvent. The residue was dissolved in dichloromethane, washed with aqueous sodium bicarbonate solution. The organic solution was separated. The aqueous solution was mixed with brine, extracted with dichloromethane (2 x 35 mL). The combined organic solution was dried over anhydrous sulfate, concentrated to afford a residue. The residue was purified with flash column chromatography on silica using 1-10% methanol in dichloromethane to afford product (118.3 mg) in 53% yield. NMR (500 MHz, Chloroform-d) delta 5.24 (s, 2H), 3.91 (t, J = 4.5 Hz, 2H), 3.42 (m, 2H), 3.33 (s, 2H), 1.43 (s, 9H), 0.96 (m, 4H). MS for C14H21 CIN6O2: 341.2 (MH+).
  • 7
  • [ 886766-28-5 ]
  • [ 98-88-4 ]
  • C18H24N2O3 [ No CAS ]
  • 8
  • [ 886766-28-5 ]
  • [ 98-88-4 ]
  • tert-butyl 4-benzoyl-4,7-diazaspiro[2.5]octane-7-carboxylate [ No CAS ]
  • 9
  • [ 39079-62-4 ]
  • [ 886766-28-5 ]
  • (E)-tert-butyl 4-(3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl)-4,7-diazaspiro[2.5]octane-7-carboxylate [ No CAS ]
  • 10
  • ethyl 2-((1-(((tert-butoxy)carbonyl)amino)cyclopropyl)carbonylamino)acetate [ No CAS ]
  • [ 886766-28-5 ]
  • 11
  • [ 24424-99-5 ]
  • 4,7-diazaspiro[2.5]octane [ No CAS ]
  • [ 886766-28-5 ]
YieldReaction ConditionsOperation in experiment
73% With sodium hydroxide; In ethanol; at 5 - 30℃; for 13h; In the 1L three-mouth reaction bottle,64.9 g of 4,7-diazaspiro[2.5]octane and 650 mL of EtOH were added in sequence.Temperature control below 30 °C,Slowly add 51g NaOH,Temperature control below 5 °C,Add 252.6g (Boc) 2O dropwise,After the addition is completed, slowly rise to room temperature. Stir the reaction at room temperature for 13 h,TLC monitors the reaction completely,filter,Desolvent,Purified by the column49.7-diazaspiro[2.5]octane-7-carboxylic acid tert-butyl ester 89.7 g,The yield was 73percent.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 886766-28-5 ]

Amides

Chemical Structure| 674792-08-6

A221123 [674792-08-6]

4-Boc-4,7-diazaspiro[2.5]octane

Similarity: 1.00

Chemical Structure| 502649-32-3

A134026 [502649-32-3]

1-Boc-3-Isopropylpiperazine

Similarity: 0.94

Chemical Structure| 886766-25-2

A137986 [886766-25-2]

1-Boc-2-Isopropylpiperazine

Similarity: 0.94

Chemical Structure| 674792-04-2

A247383 [674792-04-2]

(R)-1-Boc-2-Isopropylpiperazine

Similarity: 0.94

Chemical Structure| 674792-05-3

A252963 [674792-05-3]

(S)-1-Boc-2-Isopropylpiperazine

Similarity: 0.94

Related Parent Nucleus of
[ 886766-28-5 ]

Piperazines

Chemical Structure| 674792-08-6

A221123 [674792-08-6]

4-Boc-4,7-diazaspiro[2.5]octane

Similarity: 1.00

Chemical Structure| 502649-32-3

A134026 [502649-32-3]

1-Boc-3-Isopropylpiperazine

Similarity: 0.94

Chemical Structure| 886766-25-2

A137986 [886766-25-2]

1-Boc-2-Isopropylpiperazine

Similarity: 0.94

Chemical Structure| 674792-04-2

A247383 [674792-04-2]

(R)-1-Boc-2-Isopropylpiperazine

Similarity: 0.94

Chemical Structure| 674792-05-3

A252963 [674792-05-3]

(S)-1-Boc-2-Isopropylpiperazine

Similarity: 0.94

Spiroes

Chemical Structure| 674792-08-6

A221123 [674792-08-6]

4-Boc-4,7-diazaspiro[2.5]octane

Similarity: 1.00

Chemical Structure| 960294-18-2

A325179 [960294-18-2]

1-Boc-1,8-diazaspiro[5.5]undecane

Similarity: 0.91

Chemical Structure| 1251005-45-4

A197624 [1251005-45-4]

tert-Butyl 1,6-diazaspiro[3.5]nonane-1-carboxylate

Similarity: 0.89

Chemical Structure| 1086398-02-8

A764534 [1086398-02-8]

tert-Butyl 2,5-diazaspiro[3.4]octane-2-carboxylate

Similarity: 0.89

Chemical Structure| 127199-44-4

A133893 [127199-44-4]

(R)-tert-Butyl 5-azaspiro[2.4]heptan-7-ylcarbamate

Similarity: 0.84